
Bavarian Nordic A/S bags US$120m for smallpox vaccine
Under a deal with the US agency BARDA, Bavarian Nordic A/S (Copenhagen) will cash in US$96m in 2023 ffor the manufacturing of a n new buk product of...

Alianza Team invests in microbial oil maker Clean Food Group
Under a new collaboration agreement, Agronomics Ltd's portfolio company Clean Food Group gets a cash injection from the South American lipid,...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

Gleamer raises €27m in Series B funding round
Gleamer SAS’ financing round was led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance...

Smarter, faster, cheaper: Veeva shows how
Achieving the highest possible speed in innovation to meet patients’ unmet needs. That was the palpable goal all the pharmaceutical and life sciences...

Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

EU Regulation of Genome Editing in Plants – not yet a law
The EU proposal has a clear message: the requirements for simple genome-edited plants shall be significantly relaxed. There will no longer be the...